As the most comprehensive resource available for those involved in technology-based economic development, SSTI offers the services that are needed to help build tech-based economies. Learn more about membership...
NIH, Partners Announce $230M Accelerating Medicines Partnership
The National Institutes of Health (NIH) recently announced the Accelerating Medicines Partnership (AMP), a new public-private venture to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease. The Federal Drug Administration, 10 leading biopharmaceutical companies and several nonprofit organizations will partner with NIH to achieve the goals of increasing the number of new diagnostics and therapies for patients and reducing the time and cost of developing them. The first phase of AMP will begin with pilot projects in three disease areas:
- Alzheimer’s disease;
- Type 2 diabetes; and,
- Autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus).
Administered by the Foundation for the NIH, NIH and its partners will commit up to $230 million in expertise and resources for up to five years. A critical component of the partnership is that industry partners have agreed to make the AMP data and analyses publicly accessible to the broad biomedical community. Read the announcement…